American Century多部门浮动收益主动型ETF FUSI 深 沪
已收盘 05-22 16:00:00 美东时间
50.515
0.000
0.00%
华盛通- 最 高50.52
- 今 开50.52
- 成交量 289股
- 最 低 50.51
- 昨 收 50.515
- 总市值 2273.18万
- 52周最高 50.5799
- 市盈率 静 --
- 换手率 0.06%
- 52周最低 47.8047
- 委 比 60.00%
- 总股本 45.00万
- 历史最高 50.52
- 量 比 0.16
- 振 幅 0.02%
- 历史最低 41.0048
- 每 手 1
- 风险率 0.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Fusion Finance Resolves Depository Issue, Wins Trading Nod for Rights Issue Shares
Fusion Finance Ltd ( ($IN:FUSION) ) just unveiled an update. Fusion Finance Lim...
04-07 05:33
BRIEF-Nuvation Bio Announces Acquisition Of Japan Rights To Safusidenib From Daiichi Sankyo
BRIEF-Nuvation Bio Announces Acquisition Of Japan Rights To Safusidenib From Daiichi Sankyo April 1 (Reuters) - Koge Micro Tech Co Ltd 4568.TWO : NUVATION BIO ANNOUNCES ACQUISITION OF JAPAN RIGHTS TO SAFUSIDENIB FROM DAIICHI SANKYO NUVATION BIO INC - BUYS JAPAN RIGHTS TO SAFUSIDENIB FROM DAIICHI SAN
04-01 21:11
BRIEF-Nvidia Ai Ecosystem Expands As Marvell Joins Forces Through Nvlink Fusion
BRIEF-Nvidia Ai Ecosystem Expands As Marvell Joins Forces Through Nvlink Fusion March 31 (Reuters) - NVIDIA Corp NVDA.O : NVIDIA AI ECOSYSTEM EXPANDS AS MARVELL JOINS FORCES THROUGH NVLINK FUSION NVIDIA CORP - INVESTS $2 BILLION IN MARVELL NVIDIA CORP - CO AND MARVELL TO COLLABORATE ON SILICON PHOTO
03-31 20:30
BRIEF-Sanofi’s Sarclisa Subcutaneous Formulation Via On-Body Injector Recommended For EU Approval
BRIEF-Sanofi’s Sarclisa Subcutaneous Formulation Via On-Body Injector Recommended For EU Approval March 27 (Reuters) - Sanofi SA SASY.PA : SANOFI’S SARCLISA SUBCUTANEOUS FORMULATION ADMINISTERED VIA ON-BODY INJECTOR RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT MULTIPLE MYELOMA IF APPROVED, SARCL
03-27 20:03
BRIEF-Fusion Fuel Approves Appointment Of Uranium Investor James Passin To Board As Company Undertakes Uranium Royalty Strategy
BRIEF-Fusion Fuel Approves Appointment Of Uranium Investor James Passin To Board As Company Undertakes Uranium Royalty Strategy Fusion Fuel Green PLC HTOO.O : FUSION FUEL APPROVES APPOINTMENT OF URANIUM INVESTOR JAMES PASSIN TO BOARD AS COMPANY UNDERTAKES URANIUM ROYALTY STRATEGY Source text: ID:nGN
03-23 20:12
BRIEF-Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic
BRIEF-Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic March 17 (Reuters) - HCW Biologics Inc HCWB.O : HCW BIOLOGICS CLOSES EXCLUSIVE WORLDWIDE LICENSE FOR HCW11-006 – A HIGH POTENTIAL FUSION IMMUNOTHERAPEUTIC HCW BIOLOGICS INC - RECEIVES $7.
03-17 19:51
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib
Biomea Fusion (NASDAQ: BMEA) shares rose Friday after the company reported positive Phase II data for icovamenib in type 2 diabetes, highlighting durable efficacy and a favorable safety profile.
03-14 23:51
BRIEF-Sumitomo Corp - Investment In U.S.-Based Fusion Company Shine Technologies
BRIEF-Sumitomo Corp - Investment In U.S.-Based Fusion Company Shine Technologies March 10 (Reuters) - Sumitomo Corp 8053.T : SUMITOMO CORP - INVESTMENT IN U.S.-BASED FUSION COMPANY SHINE TECHNOLOGIES Source text: [ID:] Further company coverage: 8053.T
03-10 09:04
BRIEF-Zoox Launching Operations In Arizona, Beginning With Phoenix, Expanding Testing In Texas To Dallas
BRIEF-Zoox Launching Operations In Arizona, Beginning With Phoenix, Expanding Testing In Texas To Dallas March 9 (Reuters) - Amazon.com Inc AMZN.O : ZOOX: OPENING THIRD ZOOX FUSION CENTER FACILITY IN SCOTTSDALE, ARIZONA ZOOX: LAUNCHING OPERATIONS IN ARIZONA, BEGINNING WITH PHOENIX, EXPANDING TESTING
03-09 21:00
Fusion Finance seeks SEBI-compliant reclassification of promoter holdings as public
Fusion Finance Ltd ( ($IN:FUSION) ) has shared an update. Fusion Finance Limite...
03-03 00:45
